Achieving high sensitivity and concordance from CGP from “liquid biopsy” specimens

Comprehensive Genomic Profiling (CGP) of whole blood “liquid biopsy” specimens from cancer patients is being performed in increasing numbers when tumor tissue is inaccessible or unavailable. Consequently, a thorough validation is critical in establishing clinical utility.

In this workshop, we will discuss important considerations when establishing a ctDNA CGP assay to ensure high sensitivity and concordance; share practical implementation challenges and proposed solutions experienced in a community-based, Integrated Network Cancer Program.  We will also highlight the benefits of in-house CGP testing for both tissue and liquid. 

William LaFramboise, PhD
Chief Genomics Technology Officer
Allegheny Health Network